ADMS - Adamas Pharmaceuticals, Inc.
| Previous Close | 7.99 |
| Open | 7.95 |
| Bid | 7.65 x 800 |
| Ask | 7.90 x 1100 |
| Day's Range | 7.66 - 7.99 |
| 52 Week Range | 7.42 - 32.90 |
| Volume | 293,236 |
| Avg. Volume | 593,293 |
| Market Cap | 210.259M |
| Beta (3Y Monthly) | 2.26 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -4.87 |
| Earnings Date | Nov 1, 2017 - Nov 6, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.78 |
- GlobeNewswire•11 days ago
Adamas Announces New Employment Inducement Grant
EMERYVILLE, Calif., March 12, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted.
- Thomson Reuters StreetEvents•15 days ago
Edited Transcript of ADMS earnings conference call or presentation 4-Mar-19 9:30pm GMT
Q4 2018 Adamas Pharmaceuticals Inc Earnings Call
- Motley Fool•18 days ago
Why Adamas Pharmaceuticals Shares Are Crashing Today
Slowing growth for its flagship drug leads to analysts' downgrades.
- Benzinga•18 days ago
The Daily Biotech Pulse: Novartis Psoriasis Drug Found Superior, Ascendis Offering, Adamas Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on March 4) Abbott Laboratories (NYSE: ABT ) Ascendis Pharma A/S ...
Motley Fool•18 days agoAdamas Pharmaceuticals Inc (ADMS) Q4 2018 Earnings Conference Call Transcript
ADMS earnings call for the period ending December 31, 2018.
- GlobeNewswire•19 days ago
Adamas Reports Recent Achievements and Financial Results for the Fourth Quarter and Full-Year 2018
EMERYVILLE, Calif., March 04, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today reported recent achievements and financial results for the fourth quarter and full-year.
- Zacks•25 days ago
Will R&D Focus Fuel DENTSPLY SIRONA's (XRAY) Earnings in Q4?
DENTSPLY SIRONA's (XRAY) overall growth strategy depends on product innovation and R&D focus, which is likely to drive the top line in Q4.
- Zacks•last month
Adamas Pharmaceuticals (ADMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Adamas (ADMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- GlobeNewswire•last month
Adamas to Present at Two Upcoming Investor Conferences
EMERYVILLE, Calif., Feb. 20, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central.
- GlobeNewswire•last month
Adamas to Announce Fourth Quarter and Year-End 2018 Financial Results and Host Conference Call on March 4, 2019
EMERYVILLE, Calif., Feb. 20, 2019 -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the company will report fourth quarter and year-end 2018 financial results.
- Zacks•last month
Tenet Healthcare (THC) Q4 Earnings: What's in the Offing?
Tenet Healthcare's (THC) Q4 earnings are likely to suffer lower admissions due to divestitures.
- Zacks•last month
Can Segmental Growth Fuel Veeva Systems' (VEEV) Q4 Earnings?
Focus on cloud-based services is likely to boost Veeva Systems' (VEEV) fiscal Q4 results.
- Zacks•last month
AptarGroup (ATR) to Report Q4 Earnings: What's in Store?
AptarGroup (ATR) fourth-quarter results will benefit from successful product roll outs and focus on improving operations despite input cost inflation and customer plant shutdowns.
- Simply Wall St.•last month
Should You Be Worried About Insider Transactions At Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS)?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! We've lost count of how many timesRead More...
- Zacks•last month
Is a Beat in Store for Molina Healthcare (MOH) Q4 Earnings?
Molina Healthcare (MOH) is expected to gain in Q4 on the back of membership strength and its streamlining initiative. However, the same might be partly offset by a dismal Marketplace business.
- GlobeNewswire•last month
Report: Exploring Fundamental Drivers Behind Roku, AECOM, 1-800 FLOWERS.COM, Eldorado Resorts, Haverty Furniture Companies, and Adamas Pharmaceuticals — New Horizons, Emerging Trends, and Upcoming Developments
NEW YORK, Feb. 07, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- ACCESSWIRE•2 months ago
LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index
LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...
- Motley Fool•2 months ago
Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
A volatile stock market dished out an extra dose of punishment to riskier assets, including these three small-cap pharma companies.
- GlobeNewswire•2 months ago
Adamas Provides Preliminary Fourth Quarter and Full-Year 2018 GOCOVRI™ Sales Results and Outlines Key Priorities for 2019
Adamas Pharmaceuticals, Inc. (ADMS), a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system (CNS) disorders, today outlined key business priorities for 2019 and provided preliminary 2018 sales results for GOCOVRI™ (amantadine) extended release capsules. GOCOVRI is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy and only medication clinically proven to reduce both dyskinesia and OFF in that population.
- Benzinga•3 months ago
The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas
Here's a roundup of top developments in the biotech space over the last 24 hours. No biotech stocks hit 52-week highs Tuesday. Down In The Dumps (Biotech stocks hitting 52-week lows on Dec. 18) Accelerate ...
- GlobeNewswire•3 months ago
Adamas Announces Issuance of New U.S. Patent Covering GOCOVRI™
The USPTO has now issued a total of 14 patents from three separate patent families in the GOCOVRI patent portfolio, which now has patents expiring from 2025 to 2034. The ‘971 patent will be listed in the U.S. Food and Drug Administration’s (FDA) Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. GOCOVRI (amantadine) extended release capsules is the first and only FDA-approved medicine indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
- Insider Monkey•3 months ago
Is Adamas Pharmaceuticals Inc (ADMS) A Good Stock To Buy?
Insider Monkey has processed numerous 13F filings of hedge funds and famous investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds and investors’ positions as of the end of the third quarter. You can find write-ups about an individual hedge fund’s trades on numerous financial news websites. […]
- Motley Fool•3 months ago
Why Adamas Pharmaceuticals, Inc. Stock Continued to Slide in November
Adamas Pharmaceuticals' valuation took yet another hit last month. Here's why.
